TEVA PHARMACEUTICAL INDUSTRIES LTD【TEVA】Balance sheet
Market cap
$36.7B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Cash and cash equivalents | 1,248 | 1,096 | 2,879 | 1,038 | 2,226 | 6,946 | 988 | 963 | 1,782 | 1,975 | 2,177 | 2,198 | 2,834 | 3,227 | 3,300 |
| Marketable securities, current | 36 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total cash & short-term investments | 1,284 | 1,096 | 2,879 | 1,038 | 2,226 | 6,946 | 988 | 963 | 1,782 | 1,975 | 2,177 | 2,198 | 2,834 | 3,227 | 3,300 |
| Accounts receivable, net | 5,476 | 6,213 | 5,572 | 5,338 | 5,408 | 5,350 | 7,523 | 7,128 | 5,822 | 5,676 | 4,581 | 4,529 | 3,696 | 3,408 | 3,059 |
| Inventories | 3,866 | 5,012 | 5,502 | 5,053 | 4,371 | 3,966 | 4,954 | 4,924 | 4,731 | 4,422 | 4,403 | 3,818 | 3,833 | 4,021 | 3,007 |
| Total current assets | 12,042 | 14,453 | 16,355 | 13,720 | 14,396 | 18,398 | 16,961 | 15,382 | 13,794 | 13,464 | 13,005 | 12,573 | 12,051 | 12,485 | 12,552 |
| Property, plant and equipment, net | 4,357 | 5,947 | 6,315 | 6,635 | 6,535 | 6,544 | 8,073 | 7,673 | 6,868 | 6,436 | 6,296 | 5,982 | 5,739 | 5,750 | 4,581 |
| Total non-current assets | 26,110 | 35,689 | 34,254 | 33,788 | 32,024 | 35,860 | 75,929 | 55,233 | 46,889 | 44,006 | 37,635 | 35,093 | 31,955 | 30,994 | 26,774 |
| Total assets | 38,152 | 50,142 | 50,609 | 47,508 | 46,420 | 54,258 | 92,890 | 70,615 | 60,683 | 57,470 | 50,640 | 47,666 | 44,006 | 43,479 | 39,326 |
| Long-term debt, current | - | - | - | - | - | - | - | - | - | 1,831 | 2,674 | 1,403 | 2,086 | 1,649 | 1,758 |
| Total current liabilities | 9,694 | 13,847 | 12,888 | 11,965 | 12,289 | 13,005 | 18,519 | 17,921 | 14,322 | 13,674 | 13,164 | 11,027 | 11,469 | 12,247 | 12,796 |
| Total non-current liabilities | 6,456 | 13,952 | 14,854 | 12,907 | 10,776 | 11,326 | 39,378 | 33,949 | 30,567 | 28,733 | 26,414 | 25,395 | 23,846 | 23,106 | 20,809 |
| Total liabilities | 16,150 | 27,799 | 27,742 | 24,872 | 23,065 | 24,331 | 57,897 | 51,870 | 44,889 | 42,407 | 39,579 | 36,422 | 35,315 | 35,353 | 33,606 |
| Common stock and paid-in capital | 13,295 | 13,424 | 13,524 | 13,678 | 14,171 | 17,809 | 23,463 | 23,533,000,000 | 27,266 | 27,368 | 27,500 | 27,618 | 27,745 | 27,864 | 27,822 |
| Retained earnings | 9,325 | 11,284 | 12,346 | 12,535 | 14,436 | 14,851 | 13,607 | -3,803 | -5,958 | -6,956 | -10,946 | -10,529 | -12,882 | -13,534 | -15,173 |
| Stockholders' equity | 22,002 | 22,343 | 22,867 | 22,636 | 23,355 | 29,927 | 34,993 | 18,745 | 15,794 | 15,063 | 11,061 | 11,244 | 8,691 | 8,126 | 5,380 |
| Total debt | - | - | - | - | - | - | - | - | - | 1,831 | 2,674 | 1,403 | 2,086 | 1,649 | 1,758 |
| Net debt | - | - | - | - | - | - | - | - | - | -144 | 497 | -795 | -748 | -1,578 | -1,542 |
| D/E ratio (%) | - | - | - | - | - | - | - | - | - | 12.2 | 24.2 | 12.5 | 24 | 20.3 | 32.7 |